All In Biotech

Drug Trial Radar · NCT05061550

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Apr 14, 2022

Primary completion

May 28, 2030

Study completion May 28, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Sep 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 95 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • DurvalumabDrug

    Participants will receive Durvalumab via intravenous route.

  • OleclumabDrug

    Participants will receive Oleclumab via intravenous route.

  • MonalizumabDrug

    Participants will receive Monalizumab via intravenous route.

  • Dato-DXdDrug

    Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.

  • AZD0171Drug

    Participants will receive AZD0171 via intravenous route.

  • CarboplatinDrug

    Carboplatin as chemotherapy

  • CisplatinDrug

    Cisplatin as chemotherapy

  • Pemetrexed/CisplatinDrug

    Pemetrexed/Cisplatin as chemotherapy

  • Pemetrexed/CarboplatinDrug

    Pemetrexed/Carboplatin as chemotherapy

  • Carboplatin/PaclitaxelDrug

    Carboplatin/Paclitaxel, as chemotherapy

  • VolrustomigDrug

    Participants will receive Volrustomig via intravenous route.

  • RilvegostomigDrug

    Participants will receive Rilvegostomig via intravenous route.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with pathological complete response (pCR)Time frame: From randomization to approximately 15 weeks after the first dose of study interventions
  2. Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Until Day 90 after the last dose of study interventions (Up to approximately 3 years)

Locations

97 sites in 12 countries. Site status is shown where the registry gives one.

  • Research Site

    Little Rock, Arkansas · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Oakland, California · Withdrawn

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Stuart, Florida · Completed

  • Research Site

    Gainesville, Georgia · Withdrawn

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Baltimore, Maryland · Withdrawn

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Saint Louis Park, Minnesota · Completed

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    Buffalo, New York · Withdrawn

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Chattanooga, Tennessee · Recruiting

  • Research Site

    Memphis, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Withdrawn

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Houston, Texas · Terminated

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Edmonds, Washington · Recruiting

  • Research Site

    Seattle, Washington · Recruiting

  • Research Site

    Ghent, Belgium · Recruiting

  • Research Site

    Ghent, Belgium · Completed

  • Research Site

    Roeselare, Belgium · Recruiting

  • Research Site

    Edmonton, Alberta, Canada · Completed

  • Research Site

    Winnipeg, Manitoba, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Avignon, France · Recruiting

  • Research Site

    Bobigny, France · Withdrawn

  • Research Site

    Bordeaux, France · Recruiting

  • Research Site

    Limoges, France · Recruiting

  • Research Site

    Rennes, France · Recruiting

  • Research Site

    Rouen, France · Recruiting

  • Research Site

    Suresnes, France · Recruiting

  • Research Site

    Toulon, France · Active not recruiting

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.